Host and Viral Factors Influencing the Pathogenesis of HIV-associated Neurocognitive Disorders

Overview

Journal J Neuroimmune Pharmacol

Specialties Allergy & Immunology
Neurology
Pharmacology

Date 2009 Apr 18

PMID 19373562

Citations 16

Authors

Suman Jayadev

Gwenn A Garden

Affiliations

Soon will be listed here.

Abstract

The human immunodeficiency virus (HIV) invades the central nervous system early in the course of infection and establishes a protected viral reservoir. However, neurocognitive consequences of HIV infection, known collectively as HIV-associated neurocognitive disorders (HAND), develop in only a small portion of infected patients. The precise mechanisms of pathogenesis involved in HIV-induced central nervous system injury are still not completely understood. In particular, most theories of HAND pathogenesis cannot account for either the selective vulnerability of specific neuronal populations to HIV-induced neurodegeneration or why only a subset of patients develop clinically detectable nervous system disease. Epidemiological and virological studies have identified a variety of host and viral factors that are associated with increased risk of developing HAND. Some host factors that predispose HIV-infected patients to HAND overlap with those associated with Alzheimer's disease (AD), suggesting the possibility that common pathogenic mechanisms may participate in both diseases. Here, we will review reports of host and viral factors associated with HAND and place these studies in the context of the data employed to support current theories regarding the molecular and cellular mechanisms that lead to HIV-induced neurodegeneration with additional focus on mechanisms common to AD pathogenesis.

Citing Articles

Role of NLRP3 inflammasome in central nervous system diseases.

Zhang L, Tang Y, Huang P, Luo S, She Z, Peng H Cell Biosci. 2024; 14(1):75.

PMID: 38849934 PMC: 11162045. DOI: 10.1186/s13578-024-01256-y.

HIV-1 Tat-mediated microglial inflammation involves a novel miRNA-34a-NLRC5-NFκB signaling axis.

Periyasamy P, Thangaraj A, Sunil Bendi V, Buch S Brain Behav Immun. 2019; 80:227-237.

PMID: 30872089 PMC: 6660398. DOI: 10.1016/j.bbi.2019.03.011.

HPA-axis genes as potential risk variants for neurocognitive decline in trauma-exposed, HIV-positive females.

Jacobs S, Moxley K, Womersley J, Spies G, Hemmings S, Seedat S Neuropsychiatr Dis Treat. 2018; 14:2497-2504.

PMID: 30319260 PMC: 6167976. DOI: 10.2147/NDT.S166992.

HIV-1-Associated Neurocognitive Disorders: Is HLA-C Binding Stability to β-Microglobulin a Missing Piece of the Pathogenetic Puzzle?.

Zipeto D, Serena M, Mutascio S, Parolini F, Diani E, Guizzardi E Front Neurol. 2018; 9:791.

PMID: 30298049 PMC: 6160745. DOI: 10.3389/fneur.2018.00791.

HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy.

Thangaraj A, Periyasamy P, Liao K, Sunil Bendi V, Callen S, Pendyala G Autophagy. 2018; 14(9):1596-1619.

PMID: 29966509 PMC: 6135576. DOI: 10.1080/15548627.2018.1476810.

References

Langford D, Adame A, Grigorian A, Grant I, McCutchan J, Ellis R . Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr. 2003; 34(5):467-74. DOI: 10.1097/00126334-200312150-00004. View

Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A . Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005; 11(3):265-73. DOI: 10.1080/13550280590952790. View

OBrien S, Nelson G . Human genes that limit AIDS. Nat Genet. 2004; 36(6):565-74. DOI: 10.1038/ng1369. View

Opii W, Sultana R, Abdul H, Ansari M, Nath A, Butterfield D . Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia. Exp Neurol. 2006; 204(1):29-38. PMC: 1857338. DOI: 10.1016/j.expneurol.2006.09.010. View

van Marle G, Power C . Human immunodeficiency virus type 1 genetic diversity in the nervous system: evolutionary epiphenomenon or disease determinant?. J Neurovirol. 2005; 11(2):107-28. DOI: 10.1080/13550280590922838. View

Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

Mallon P, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K . In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis. 2005; 191(10):1686-96. DOI: 10.1086/429697. View

Chiesi A, Vella S, Dally L, Pedersen C, Danner S, Johnson A . Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 11(1):39-44. DOI: 10.1097/00042560-199601010-00005. View

Turchan J, Pocernich C, Gairola C, Chauhan A, Schifitto G, Butterfield D . Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology. 2003; 60(2):307-14. DOI: 10.1212/01.wnl.0000042048.85204.3d. View

10.

Sabbah E, Roques B . Critical implication of the (70-96) domain of human immunodeficiency virus type 1 Vpr protein in apoptosis of primary rat cortical and striatal neurons. J Neurovirol. 2005; 11(6):489-502. DOI: 10.1080/13550280500384941. View

11.

Maragos W, Young K, Turchan J, Guseva M, Pauly J, Nath A . Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem. 2002; 83(4):955-63. DOI: 10.1046/j.1471-4159.2002.01212.x. View

12.

Sacktor N, Nakasujja N, Robertson K, Clifford D . HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversity. Nat Clin Pract Neurol. 2007; 3(8):436-43. DOI: 10.1038/ncpneuro0559. View

13.

Su J, Anderson A, Cummings B, Cotman C . Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport. 1994; 5(18):2529-33. DOI: 10.1097/00001756-199412000-00031. View

14.

Garden G, Guo W, Jayadev S, Tun C, Balcaitis S, Choi J . HIV associated neurodegeneration requires p53 in neurons and microglia. FASEB J. 2004; 18(10):1141-3. DOI: 10.1096/fj.04-1676fje. View

15.

Clark C, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D . Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol. 2003; 60(12):1696-702. DOI: 10.1001/archneur.60.12.1696. View

16.

Cherner M, Letendre S, Heaton R, Durelle J, Marquie-Beck J, Gragg B . Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005; 64(8):1343-7. DOI: 10.1212/01.WNL.0000158328.26897.0D. View

17.

Shiu C, Barbier E, Di Cello F, Choi H, Stins M . HIV-1 gp120 as well as alcohol affect blood-brain barrier permeability and stress fiber formation: involvement of reactive oxygen species. Alcohol Clin Exp Res. 2007; 31(1):130-7. DOI: 10.1111/j.1530-0277.2006.00271.x. View

18.

Diaz-Arrastia R, Gong Y, Kelly C, Gelman B . Host genetic polymorphisms in human immunodeficiency virus-related neurologic disease. J Neurovirol. 2004; 10 Suppl 1:67-73. DOI: 10.1080/753312755. View

19.

Dolan M, Kulkarni H, Camargo J, He W, Smith A, Anaya J . CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol. 2007; 8(12):1324-36. DOI: 10.1038/ni1521. View

20.

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B . Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999; 56(6):673-80. DOI: 10.1001/archneur.56.6.673. View